Circuitcity. Yes AMRN is definitely looking at epa levels and aa/epa ratio. This was asked at the investor conference. The science officer said they are very interested in these and aware of commercially available testing and possibly use of lab testing in predicting best patient candidates.
JFMCRR: thanks for the yogurt trick. -------- Deepak Bhatt and others - anti-thrombotic effects.
In 2012 - Dr. Bhatt and "novel therapies"
More history:
Oh, is this part of the answer to my question which was why Japan would be intensely focused on the anti-thrombotic effects of EPA EE. I wonder if its because the two populations are different as below?